All In Biotech

Free tool

FAERS Monitor: Thyrogen

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 020898 or its brand name (Thyrogen, Thyrotropin Alfa). Reports on generic versions are filed under their own applications.

Reports

1,038

Serious

353

34% of reports

Hospitalization

161

Death reported

23

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea130
  • headache83
  • fatigue82
  • off label use81
  • vomiting53
  • malaise43
  • dizziness41
  • pain41
  • drug ineffective38
  • blood thyroid stimulating hormone decreased28
  • asthenia26
  • pyrexia26
  • diarrhoea24
  • product storage error24
  • arthralgia23

Reports by year received

View as table
YearReports
200415
20057
200614
200719
200813
200917
201024
201113
201220
201366
201461
201559
201666
201761
201840
201965
202049
202174
202276
202370
2024102
202561
202646

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,121 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood thyroid stimulating hormone decreasedSignal28125.787.13,320
product storage errorSignal245.63.786
nauseaSignal1303.32.8218
headacheSignal832.72.289
vomitingSignal532.31.838
fatigueSignal822.11.750
malaise432.01.521
off label use811.91.534
dizziness411.71.211
pyrexia261.51.04
asthenia261.41.03
pain411.41.04
arthralgia231.10.70
diarrhoea240.80.52
drug ineffective380.60.412

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.